Enrique Chacon-Cruz1, Jorge Luis Arellano-Estrada2, Erika Lopatynsky-Reyes3, Jorge Alvelais-Palacios3, Chandra Becka4. 1. Hospital General de Tijuana - Pediatrics, Paseo Centario S/N Zona del Rio, Tijuana, Baja-California 22010, Mexico. 2. Health Jurisdiction of Tijuana - Epidemiology, Tijuana Baja-California, Mexico. 3. Universidad Autonoma de Baja-California Campus ECISALUD - School of Medicine, Tijuana, Baja-California, Mexico. 4. University of Texas Rio Grande Valley Ringgold Standard Institution - Internal Medicine, Brownsville, Texas, USA.
Abstract
OBJECTIVES: Vaccination against tuberculosis with live-attenuated Bacillus Calmette-Guérin (BCG) is widely used even though its effectiveness is controversial. BCG-lymphadenitis (BCG-LA) is its most common complication. Some studies have proposed that BCG-LA can be associated with primary immunodeficiencies (PIs). This study's aim is to see whether patients who developed BCG-LA (named as 'LA') developed more infections than BCG-vaccinated children without BCG-LA (named as 'NON-LA'). METHODS: From January 2009 to April 2014, 31 LA children were seen at the outpatient clinic of the General Hospital of Tijuana, Mexico. Among them, 22 (70.97%), 5 (16.13%) and 4 (12.9%) had axillary, supraclavicular, or both BCG-LA, respectively. No treatment was given and complications were not seen. Per LA subject, a NON-LA not >1 month of age difference and same gender was paired and followed for 3 years to look for ambulatory infections (AINFs), acute otitis media (AOM) and hospitalizations. Surveillance per patient was performed by phone monthly, and they were seen at the clinic every 4 months. All patients were HIV-negative and had no family history of PI. Statistical analyses used were relative risk (RR) with confidence intervals (CI), t test for independent variables and z test. RESULTS: In total 62 subjects were enrolled: 31 LA paired with 31 NON-LA. Between them, there were no differences in age, day care attendance and breastfeeding. There were no differences in the total number of AINF per patient (LA: 18.61 avg. ± 5.03 SD versus NON-LA: 18.19 avg. ± 4.17 SD, RR = 1.06, 95% CI = 0.33-0.66), AOM total episodes (LA: 30 versus NON-LA: 26, RR = 0.87, 95% CI = 0.31-0.68) and hospitalizations (LA: 5 versus NON-LA: 4, RR = 1, 95% CI = 0.25-0.74). CONCLUSIONS: This cohort strongly suggests that BCG-LA in healthy children is not associated with more episodes of AINF and hospitalizations, when paired and compared with children BCG-vaccinated without BCG-LA.
OBJECTIVES: Vaccination against tuberculosis with live-attenuated Bacillus Calmette-Guérin (BCG) is widely used even though its effectiveness is controversial. BCG-lymphadenitis (BCG-LA) is its most common complication. Some studies have proposed that BCG-LA can be associated with primary immunodeficiencies (PIs). This study's aim is to see whether patients who developed BCG-LA (named as 'LA') developed more infections than BCG-vaccinated children without BCG-LA (named as 'NON-LA'). METHODS: From January 2009 to April 2014, 31 LA children were seen at the outpatient clinic of the General Hospital of Tijuana, Mexico. Among them, 22 (70.97%), 5 (16.13%) and 4 (12.9%) had axillary, supraclavicular, or both BCG-LA, respectively. No treatment was given and complications were not seen. Per LA subject, a NON-LA not >1 month of age difference and same gender was paired and followed for 3 years to look for ambulatory infections (AINFs), acute otitis media (AOM) and hospitalizations. Surveillance per patient was performed by phone monthly, and they were seen at the clinic every 4 months. All patients were HIV-negative and had no family history of PI. Statistical analyses used were relative risk (RR) with confidence intervals (CI), t test for independent variables and z test. RESULTS: In total 62 subjects were enrolled: 31 LA paired with 31 NON-LA. Between them, there were no differences in age, day care attendance and breastfeeding. There were no differences in the total number of AINF per patient (LA: 18.61 avg. ± 5.03 SD versus NON-LA: 18.19 avg. ± 4.17 SD, RR = 1.06, 95% CI = 0.33-0.66), AOM total episodes (LA: 30 versus NON-LA: 26, RR = 0.87, 95% CI = 0.31-0.68) and hospitalizations (LA: 5 versus NON-LA: 4, RR = 1, 95% CI = 0.25-0.74). CONCLUSIONS: This cohort strongly suggests that BCG-LA in healthy children is not associated with more episodes of AINF and hospitalizations, when paired and compared with children BCG-vaccinated without BCG-LA.
Authors: M A Dommergues; F de La Rocque; C Guy; A Lécuyer; A Jacquet; N Guérin; J P Fagot; M Boucherat; Ph d'Athis; R Cohen Journal: Vaccine Date: 2009-10-01 Impact factor: 3.641
Authors: B Gonzalez; S Moreno; R Burdach; M T Valenzuela; A Henriquez; M I Ramos; R U Sorensen Journal: Pediatr Infect Dis J Date: 1989-04 Impact factor: 2.129
Authors: I Abubakar; L Pimpin; C Ariti; R Beynon; P Mangtani; J A C Sterne; P E M Fine; P G Smith; M Lipman; D Elliman; J M Watson; L N Drumright; P F Whiting; E Vynnycky; L C Rodrigues Journal: Health Technol Assess Date: 2013-09 Impact factor: 4.014
Authors: A Roy; M Eisenhut; R J Harris; L C Rodrigues; S Sridhar; S Habermann; L Snell; P Mangtani; I Adetifa; A Lalvani; I Abubakar Journal: BMJ Date: 2014-08-05